ºÝºÝߣ

health economics hta uk pharmaceuticals medicines health care innovation nhs eq-5d pricing biotechnology and pharmaceuticals nice pharmaceutical industry htai ohe r&d england health technology assessment cancer ispor adrian towse reimbursement europe proms medicine qaly antibiotics quality of life cost-effectiveness health outcomes patients incentives presentation health policy value-based pricing devlin diagnostics emerging markets drugs ispor europe 2018 indication-based pricing intellectual property pharmaceutical innovation hepatitis c discrete choice experiment stated preferences children preferences end of life economics euroqol decision modelling İç±ð°ù eq-5d-y patient-reported outcomes research competition vbp access costs germany antimicrobial resistance amr france prescription drug qalys drug development mental health mlics wellbeing net monetary benefit costa rica life-cycle value transparency rare diseases public preferences prices multi-indication pricing presentations open source patient reported outcomes utilities asia value public medical research risk research and development measurement for drugs differential pricing 2018 health status outcomes tto end-of-life direct acting antivirals quality adolescents health care systems policy cost-effectiveness analysis discrete choice genomics spillovers orphan drugs access to care elderly risperidone affordability long-term care genomic testing caregiving technology pharmaceutical big data stratified medicine unmet need next generation sequencing data analytics aai legitimate legal bases uae ed-5d health care costs pprs ldcs global health mhra ema generics biosimilars latin america end-of-life care burden of illness heor royal brompton time trade off antimicrobials real world evidence resistance antibacterials outcomes-based contracting lung cancer personalized medicine oncology patient access schemes public attitudes novel elements of value politics payers pay-for-performance specialised care national health service financial incentives innovative medicine commissioning surplus antipsychotics contracting procurement sweden funding italy second generation antipsychotics social surplus kings fund eq-vas generic competition internet survey poster health health state valuation dead death medicare health insurance usa healthcare modeling taiwan china brazil decision analysis health inequality inequality pharm international comparisons forecast value in health clinical trial cost weighted qalys augmented cea weighted cea mcda assessment australia ispe hta decision making real option value disease management multi-indication drugs indication-specific pricing washington dc ispor summit nancy devlin qaly's lou garrison ipor washing dc approaches to value assessment debate labour productivity learning outcomes international volunteering global engagement price discrimination indication price and reimbursement pharmaceutical regulation market competition health system capacity daas matching mapping uptake curves static and dynamic efficiency market access r&d incentives supplementary patent certificates indication-based-pricing economics of r&d welfare states patient-centred care fair pricing world health organisation heath technology assessment (hta) ispor barcelona globalisation barcelona ispor 2018 curative therapies challenges rewards payors regulators triangulating developers handling uncertainty payment mechanisms evidence uncertainty hta outcomes hta transferability patient involvement flexibility and transparency hta lifecycle therapeutic added value future directions modern hta good practice pharmaceutical r&d. value-based pricing and reimbursement pharmacoeconomics systematic review professional training stated preference cadth sustainability proms conference koonal shah oncology medicines outcome-based payments indication based pricing tto valuations of health states eq-5d-5l eq-5d-3l end of life medicines koonal indication specific pricing innovative payment models legal barriers healtcare decision making cea health data uhc gdpr pbrsa hip surgery us cost effectiveness icer consent dying rates of return cost-effectiveness threshold revenue cost of r&d fairness qualitative analysis interviews uptake economics of cures buget impact methodology expenditure visual analogue scale time trade-off valuation expenditure caps markov screening diabetic retinopathy real-world data real-world evidence vaccines third plenary session framing effects value of diagnostic information value of knowing universal health coverage health financing clinical evaluation